Objective. Chemokine receptors mediate leukocyte migration into inflamed rheumatoid arthritis (RA) synovial tissue (ST). Knowledge of their distribution is crucial for understanding the evolution of the inflammatory process. In this study, we used rat adjuvantinduced arthritis (AIA), a model for RA, to define the temporospatial expression of chemokine receptors.
receptors are used sequentially, thereby serving a unique function in the migratory process (7) . The putative complexity and redundancy emphasize the importance of both spatially and temporally well-defined secretion and presentation of chemokines and chemokine receptors in the synovial tissue (ST), as well as regulated expression of their counterparts on leukocytes during differentiation and activation (8) .
To determine the specific role of chemokine receptors in the pathogenesis of RA and to design interventional approaches accordingly, it is important to understand the temporospatial expression of chemokine receptors in the development of inflammatory arthritis. The present study was undertaken to elucidate this.
MATERIALS AND METHODS
Induction of rat adjuvant-induced arthritis (AIA) and tissue sampling. Female Lewis rats (100 gm) were injected subcutaneously at the base of the tail with 300 l (5 mg/ml) lyophilized Mycobacterium butyricum (Difco, Detroit, MI) in sterile mineral oil on day 0. Rats were killed at various times post-adjuvant injection, and joints harvested.
Immunohistochemistry. Immunohistochemistry studies were performed on ST cryosections (8 m) from rats with AIA, for the chemokine receptors CCR5, CXCR4 (polyclonal goat antibodies cross-reacting with human, mouse, and rat; Santa Cruz Biotechnology, Santa Cruz, CA), CCR1, CCR2, CCR3, CCR4 (polyclonal rabbit antibodies cross-reacting with human, mouse, and rat; Santa Cruz Biotechnology), CXCR1, CXCR2, CXCR3, and CXCR5 (monoclonal mouse antihuman antibodies; R&D Systems, Minneapolis, MN). Antibody concentration was 2 g/ml for CCR1-5 and CXCR4, and 10 g/ml for CXCR1, CXCR2, and CXCR5. Isotype-matched nonspecific IgG was used as a negative control. Immunostaining was performed using Elite ABC kits (Vector, Burlingame, CA) and diaminobenzidine (Kirkegaard & Perry, Gaithersburg, MD) as a chromogen, followed by counterstaining with hematoxylin.
Microscopic analysis. ST elements examined included lining cells, macrophages, ECs, lymphocytes, and smooth muscle cells. Immunostaining was evaluated under blinded conditions and graded by a pathologist as described previously (9) . Cell types were distinguished based on their characteristic morphology and/or immunohistochemical staining reaction (9) (10) (11) . Macrophages were distinguished from fibroblasts based on morphology and immunoreactivity with monoclonal mouse anti-rat CD11b/c antibody (monocyte/macrophage marker; BD PharMingen, Franklin Lakes, NJ). Endothelium was verified using anti-von Willebrand factor (anti-vWF; Dako, Carpinteria, CA), synovial lining cells were determined based on morphologic features, and lymphocytes were identified by their characteristic nuclear morphology and chromatin pattern. Each ST component was graded for frequency of staining on a scale of 0-100%, where 0% indicates no staining and 100% indicates that all cells were immunoreactive. The percentage of reactivity was defined as the number of cells of a given type reacting with a specific antibody divided by the total number of cells of that given type. To confirm identification of macrophages, CD11b/c-positive cells coexpressing CCR1 and CXCR4 were determined using double staining. Lymphocytes were identified by CD3 staining. In addition, an inflammation score was obtained using the following scoring system: 1 ϭ normal; 2 ϭ increased number of inflammatory cells, arrayed as individual cells; 3 ϭ increased number of inflammatory cells including distinct clusters (aggregates); and 4 ϭ marked diffuse infiltrate of inflammatory cells. Score data were pooled, and the mean Ϯ SEM was calculated in each data group.
Cell culture. NR8383 cells, a rat alveolar macrophage cell line (American Type Culture Collection, Manassas, VA), were maintained in Ham's F-12 medium (Invitrogen, Carlsbad, CA) containing 20% fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mM glutamine at 37°C/5% CO 2 . Cells (20,000/well) were cultured in 8-well Labtek chamber slides (BD PharMingen) until confluence was reached. The medium was changed to serum-free Ham's F-12 before stimulation for 3 hours with lipopolysaccharide (LPS; 10 g/ml) (12) .
Immunofluorescence. NR8383 cells were used for immunofluorescence staining after formalin fixation. Similarly, double immunofluorescence analysis was performed on ST from rats with AIA to determine colocalization of chemokine receptors with synovial cells, using the EC-specific rabbit anti-human vWF antibody, mouse anti-rat CD11b/c, or the T cell marker CD3. After blocking, tissues or cells were incubated with the primary antibodies for chemokine receptors, cell type markers, or control IgG, respectively. For detection, the following immunofluorescence dye-tagged secondary antibodies (1:200 in phosphate buffered saline) were used: Alexa Fluor 568-conjugated stained goat anti-rabbit antibody, Alexa Fluor 488-conjugated donkey anti-rabbit antibody, and Alexa Fluor 488-conjugated donkey anti-goat antibody (all from Molecular Probes, Eugene, OR). Nuclear staining was performed with 4Ј,6-diamidino-2-phenylindole-dihydrochloride (Molecular Probes). Immunofluorescence staining was detected using a BX51 fluorescence microscope system (Olympus, Melville, NY) with DP Manager imaging software. CD11b/c-positive cells in ST from rats with AIA, reflecting the influx of monocyte/macrophages, were assessed by counting the number of cells in 5 high-power fields (hpf; 400ϫ) and calculating the average number of cells per hpf. CD11b/c-coexpressing CCR1 and CXCR4 were determined in the same way and presented as the percentage of chemokine receptor-positive cells per CD11b/c-expressing cell.
Statistical analysis. Values are presented as the mean Ϯ SEM. Statistical analysis was performed using Student's t-test. P values less than 0.05 were considered significant. Pearson correlation coefficients were assessed to describe the relationships of various parameters, using the mean from each time point during AIA.
RESULTS
Course of inflammation in rat AIA. Rats with AIA started showing clinical signs of inflammation on days 7-14 post-adjuvant injection. Histologic assess Up-regulation of constitutive CCR1 expression in rat AIA. Among the important receptors in RA is CCR1, with its ligands RANTES/CCL5 and macrophage inhibitory protein 1␣ (MIP-1␣)/CCL3. CCR1 expression in ST macrophages was constitutive and showed an increase on day 25 post-adjuvant injection (which was the time of maximum joint inflammation), with a subsequent decline to baseline expression on day 54, as determined by both immunohistochemistry and immunofluorescence ( Figures 1A and B) . Surprisingly, lining cells also exhibited major constitutive expression of CCR1, which tended to increase at the peak of inflammation with a subsequent decline, the number mirroring CCR1 expression on macrophages (r ϭ 0.86) ( Figures 1A and C) . Expression of CCR1 on lining cells also correlated with the histologic inflammation score (r ϭ 0.80) ( Figure 1C ), while ECs and lymphocytes were nonreactive for CCR1 (data not shown).
Role of CCR2 in the initial recruitment of peripheral blood monocytes to ST in rats with AIA. Macrophages in normal rat ST were only occasionally immunopositive for CCR2, a receptor for monocyte chemoattractant protein 1 (MCP-1)/CCL2, but in macrophages from rats with AIA, CCR2 levels tended to be increased on day 14 post-adjuvant injection and thereafter ( Figure 2A ). In contrast, ST ECs showed constitutive expression of CCR2 that remained high in early AIA (Figures 2A and B ), but decreased dramatically by day 18 (with the decrease persisting to day 25 [at the peak of inflammation] [P Ͻ 0.05]) and tended to increase thereafter. These data suggest a role for CCR2 on ECs in early leukocyte recruitment and transendothelial migration. Moreover, EC expression of CCR2 was inversely correlated with both the degree of inflammation (r ϭ Ϫ0.85) and CCR2 expression on lining cells (r ϭ Ϫ0.85) ( Figure 2C ). CD3ϩ lymphocytes expressed CCR2 only occasionally ( Figure 2B ).
Inverse correlation of CCR1 and CCR2 expression on ST in AIA. Figure 2D shows the interrelation of CCR1 and CCR2 expression on macrophages and in smooth muscle cells in rat AIA. Interestingly, the pattern of expression of CCR2 on those cell types was almost inverse to that of CCR1 expression on macrophages. This observation was corroborated by observations of CCR1 and CCR2 expression on smooth muscle cells in ST of rats with AIA at different time points compared with day 0. CCR2 was amply constitutively expressed in smooth muscle cells but showed a trend toward decreased immunoreactivity on days 7 and 14 of AIA, followed by a slight rebound. In contrast, CCR1 expression on normal ST smooth muscle cells was low, but increased on day 14 with a subsequent decline to baseline values, underscoring the different time and nature of action of the 2 receptors in leukocyte recruitment and retention in rat AIA.
Role of CCR3 in early AIA in rats. CCR3, a receptor for RANTES/CCL5 and eotaxin/CCL11, was present on macrophages in rats with early AIA (mean Ϯ SEM 42 Ϯ 11%), but expression tended to decrease during the course of AIA (23 Ϯ 14% on day 18) ( Figures  3A and B) , supporting the notion of their initial involvement in leukocyte recruitment to the joint. CCR3 expression on lining cells in ST of rats with AIA exhibited a similar time course ( Figure 3A) , emphasizing the role of the receptor in this context. Conversely, ECs barely expressed CCR3, and lymphocytes did not show significant immunopositivity (data not shown), as confirmed by immunofluorescence costaining with CD3.
CCR4 expression on synovial endothelium promotes leukocyte recruitment in rats with early AIA. CCR4, a receptor for thymus and activation-regulated chemokine (TARC)/CCL17 and macrophage-derived chemokine (MDC)/CCL22, may be particularly important for CD3ϩ,CD4ϩ memory T cell migration to synovium in RA (13, 14) . As shown in Figure 3C , constitutive CCR4 EC expression was down-regulated as inflammation progressed, supporting the idea that CCR4 has a specific role in leukocyte recruitment in the early phase of AIA. In contrast, CCR4 expression on macrophages was weak and unaltered, coinciding with the finding that ST lining cells and lymphocytes did not express CCR4 in AIA (data not shown).
Importance of CCR5 expression on macrophages for sustaining the inflammatory changes in rat AIA. Investigators at our laboratory have shown previously that CCR5, the receptor for RANTES/CCL5, MIP-1␣/ CCL3, and MIP-1␤/CCL4, is up-regulated at the protein and messenger RNA (mRNA) levels on various ST cells during peak inflammation in rat AIA (11) . In the present study we expanded those data by defining CCR5 expression at the protein level at different time points during the course of AIA in the context of the expression patterns of other chemokine receptors.
Rat ST macrophages exhibited weak constitutive expression of CCR5 that tended to be up-regulated in AIA starting on day 7, with a significant increase on day 54 (P Ͻ 0.05) ( Figures 4A and B) , suggesting a distinct role for CCR5 and its ligands particularly in maintaining the inflammatory process. CCR5 expression on macrophages correlated well with CCR5 immunoreactivity on lining cells (r ϭ 0.90) and tended to have a course similar to that of macrophage staining for CCR2 (r ϭ 0.76), suggesting a close pathophysiologic relationship of the 2 chemokine receptors ( Figure 4C ). Immunofluorescence analysis for CCR5 and CD11b/c on day 18 confirmed colocalization of CCR5 in rat macrophages, revealing both cytoplasmic and cell surface expression ( Figure  4D ). ECs showed only weak CCR5 expression, with a moderate, but not statistically significant, increase in early AIA ( Figure 4A ), while lymphocytes were essentially immunonegative for the receptor (data not shown).
CXCR4 expression on ECs precedes the peak of inflammation in rat AIA. CXCR4, the receptor for stromal cell-derived factor 1 (SDF-1)/CXCL12 (which plays a critical role in monocyte localization to inflamed RA synovium [15] , as well as in promoting neovascularization in RA ST [16] ), showed prominent expression on ECs starting on day 14 (P Ͻ 0.05) ( Figure 5A ). CXCR4 expression preceded the peak of inflammation and was followed by a slow decline until day 54, emphasizing its potential role in retention of inflammatory effector cells in the joint ( Figure 5A ). Double immunofluorescence studies for vWF and CXCR4 confirmed the endothelial expression during the course of rat AIA ( Figure 5C ). Normal macrophages (i.e., day 0) expressed minimal CXCR4, but expression of the receptor on macrophages was increased starting on day 18 of AIA (P Ͻ 0.05) ( Figures 5A and B) . In addition, immunofluorescence staining revealed CXCR4 expression predominantly on the cell surface ( Figure 5D ). In contrast, ST lining cells expressed CXCR4 constitutively (mean Ϯ SEM 22 Ϯ 9%), followed by significant CXCR4 down-regulation in the early phase of AIA (P Ͻ 0.05) ( Figure 5A ). Again, lymphocytes in ST from rats with AIA only occasionally expressed CXCR4, and costaining with the T cell marker CD3 corroborated these findings (data not shown).
Chemokine receptor expression on stimulated NR8383 cells reflects the in vivo situation in early AIA in rats. To investigate whether expression of chemokine receptors on rat macrophages in vitro reflects in vivo conditions and if expression changes in response to a proinflammatory stimulus, we used the rat macrophage cell line NR8383 to determine baseline expression and intracellular distribution before and after stimulation with LPS ( Figure 6A ). NR8383 cells showed intense constitutive, predominantly cytoplasmic, expression of CCR1 which was not affected by LPS stimulation, corroborating the in vivo data. NR8383 cells demon- strated less CCR2 expression both with and without LPS stimulation, also paralleling the results obtained for CCR2 staining on normal and AIA ST. Likewise, CCR4 could not be detected on NR8383 cells in vitro (results not shown), while high constitutive cell surface expression of CCR3 showed a slight decrease in response to LPS. Surprisingly, stimulation of quiescent NR8383 cells resulted in clear up-regulation of CCR5. In contrast, a faint but distinct cell surface pattern for CXCR4 essentially did not change after LPS treatment.
CXCR1 expression on smooth muscle cells in rat ST. Immunohistochemistry analysis for CXCR1 in normal rat ST ( Figure 6B ) showed constitutive expression on smooth muscle cells (mean Ϯ SEM 9 Ϯ 7%), which tended to be decreased on day 18 of rat AIA (4 Ϯ 3%) and thereafter (2 Ϯ 1% on day 54). Conversely, in lining cells and macrophages, CXCR1 expression was increased during rat AIA compared with expression in normal rats (P Ͻ 0.05 for macrophages on day 18).
Role of CXCR2, CXCR3, and CXCR5 in rat synovium. Evaluation of additional CXC chemokine receptors in normal and arthritic rat ST demonstrated expression only on lining cells and macrophages ( Figure  6C ), but virtually no staining on ECs or lymphocytes (data not shown). CXCR2, a receptor for the human chemokines growth-related oncogene ␣/CXCL1 and 1,000) . B, Percentages of various cell types stained for CXCR1 on day 18 and day 54 in rats with AIA, compared with findings in normal rats (day 0). CXCR1 was constitutively expressed on smooth muscle cells, followed by a decline during rat AIA. Conversely, lining cells showed a trend toward increased CXCR1 expression over time, and macrophages showed de novo expression of CXCR1 on day 18 of rat AIA, which was significant compared with findings in normal rat ST macrophages. Values are the mean and SEM. C, Trends in CXCR2, CXCR3, and CXCR5 expression on lining cells and macrophages in ST from rats with AIA on day 18 and day 54 post-adjuvant administration, compared with day 0. Values are the mean. See Figure 1 for other definitions. Color figure can be viewed in the online issue, which is available at http://www.arthritisrheum.org.
receptor for B cell-attracting chemokine 1/CXCL13, showed baseline expression on lining cells with a trend toward a decrease during the course of AIA.
DISCUSSION
Chemokines and their receptors have increasingly been considered to be interesting potential targets for therapy in RA (17) . The prevailing paradigm is that leukocyte influx into the joint is orchestrated through a sophisticated network of expressed chemokine receptors and their ligands. Thus, knowledge of defined expression patterns is needed in order to develop means of blocking chemokine interactions with their receptors, thus modifying the inflammatory process.
In human RA, CCR1-positive cells, mainly macrophages, are scattered throughout the synovium (14) . Studies of CCR1 disruption in mice have yielded conflicting results regarding inflammatory responses, with both abrogation (18) and enhancement (19) being observed. However, blocking of CCR1 ligands resulted in impaired monocyte migration in vitro in response to RA SF and in reduced synovial inflammation and joint destruction in rodent models of RA (20, 21) . Moreover, a double-blind, placebo-controlled, phase Ib clinical trial using an oral CCR1 antagonist showed improved histologic features in ST of patients with RA (17) .
In our study, constitutive CCR1 expression on ST lining cells tended to increase at the time of maximum inflammation in AIA. ST macrophages also showed constitutive expression of CCR1, with a significant increase at the time of peak inflammation on day 25, supporting findings in human RA (14) . Surprisingly, we observed cytoplasmic and cell surface expression of CCR1 both in vivo and in vitro, potentially indicating a yet-unknown function of this receptor. These results suggest that CCR1 has a distinct role in recruiting and retaining leukocytes in rat AIA, and underscore our recent finding that blocking of CCR1 in rat AIA significantly reduced joint inflammation and monocyte/ macrophage influx (22) . These data also parallel findings on the fractalkine receptor CX 3 CR1 in rats, i.e., lack of EC staining but high constitutive macrophage staining, maintained during AIA (10) .
CCR2 is expressed on T cells and monocytes infiltrating human RA ST (23) . In studies of blocking of the CCR2 ligand MCP-1/CCL2, there was partial improvement of murine arthritis (24) . Surprisingly, in a collagen-induced arthritis (CIA) model, the disease was worse in CCR2 gene-deficient mice compared with wild-type controls (25) ; this suggested that CCR2 can serve as a negative regulator of arthritis onset and severity, conflicting with the current paradigm and implicating a more variable role of CCR2 than initially anticipated. In the present study, CCR2 protein expression was occasionally observed in macrophages from normal rat ST and tended to increase slightly on day 14 of AIA and thereafter, while expression of CCR2 mRNA in the whole joint has been shown to be clearly up-regulated at the time of maximum inflammation (11) .
Interestingly, immunoreactivity for CCR2 on ECs was high constitutively as well as in early AIA, but had decreased dramatically by day 18 post-adjuvant administration, correlating negatively with the degree of inflammation. This distinctive expression of a chemokine receptor on endothelium, varying over time, may result in temporospatially specific leukocyte adhesion and transmigration, thus controlling the inflammatory process (26) . Recently, Dzenko et al showed that CCR2 expression by ECs is critical for macrophage transendothelial migration in the brain (27) . Our findings suggest that CCR2 on ECs mediates leukocyte recruitment in early AIA by facilitating transendothelial migration of mononuclear cells, but may function in a different way at a later time point. This notion of a dual role is supported by the results of a study in which blockade of CCR2 during the early phase of CIA resulted in improved clinical signs of arthritis and histologic scores, whereas arthritis was aggravated following CCR2 blockade in late stages of CIA (28) .
Of note, on macrophages and smooth muscle cells, CCR2 expression and CCR1 expression displayed inverse patterns over time, thereby indicating essentially different roles of the 2 chemokine receptors in recruiting and retaining leukocytes in rat AIA. Both CCR1 and CCR2 have previously been reported to be expressed by human vascular smooth muscle cells in vitro (29) , which could explain the ability of smooth muscle cells to respond to certain chemokines, thereby modifying proliferation and migration. The significance of this observation in the context of RA, however, needs further evaluation.
CCR3 was initially thought to be specific for eosinophils but was subsequently identified to mediate T cell recruitment (30) . CCR3 has been demonstrated to be moderately expressed on CD14ϩ peripheral blood monocytes in patients with RA, while normal control subjects showed minimal expression (14) , thereby indicating a potential role of CCR3 in monocyte recruitment. In the present study, CCR3 was detected on ST macrophages and lining cells in early AIA with a subsequent trend toward declining expression, supporting the idea of initial involvement in leukocyte trafficking to the synovial joint. High constitutive expression of CCR3 on rat ST macrophages was confirmed in experiments with resting rat macrophages in vitro, with only a slight decrease after LPS stimulation, reflecting the in vivo situation.
CCR4, initially thought to be restricted to T cells and basophils, has subsequently been detected on peripheral blood monocytes of RA patients (14) . In human RA ST, however, CCR4 was not detected on macrophages (14) . Findings of other studies support the idea that CCR4 may be crucial to the pathogenesis of RA (13, 31) , although only limited data on the role of the CCR4 ligands TARC/CCL17 and MDC/CCL22 are available (32, 33) . The weak expression of CCR4 on synovial macrophages as well as its virtual absence on lining cells in rat AIA are supportive of the hypothesis that this receptor does not have an essential proinflammatory role, despite the observation that total CCR4 mRNA expression in joints increased during rat AIA (11) . In some studies, CCR4 has even been considered to have an antiinflammatory role (14, 34) . In contrast, constitutive CCR4 expression in ECs was significantly down-regulated during inflammation, suggesting a possible role of CCR4 in leukocyte recruitment and transmigration in the early phase of AIA. Interestingly, CCR4-deficient mice are resistant to LPS-induced endotoxic shock, indicating a defect in macrophage function (35) . It would be very informative to observe the effect of CCR4 deletion in an arthritis model.
Of particular interest regarding therapeutic intervention in RA is CCR5, although in a recent study the course of CIA was not significantly modified in CCR5-deficient mice (25) . However, in a nonhuman primate model of RA, treatment with a CCR5 antagonist resulted in clinical improvement of the disease (36), supporting the notion that this chemokine receptor has a pathogenic role in arthritis and providing strong evidence for the potential value of therapy targeting this receptor.
In the present study, CCR5 expression on synovial macrophages showed a trend toward up-regulation starting on day 7, with significantly increased levels of CCR5-immunopositive macrophages on day 54, confirming observations in ST of humans with RA (14) . CCR5 expression on lining cells showed a similar pattern, with protein expression following up-regulation of CCR5 in the joint at the mRNA level (11) . These data suggest a distinct role for CCR5 and its ligands, particularly in maintaining the inflammatory process. However, CCR5 up-regulation on rat macrophages in response to LPS, together with increased CCR5 expression in vivo, may indicate an important pathophysiologic role over time in arthritis. An array-based analysis of not-yet-inflamed joints in mice with autoimmune arthritis identified CCR5 as one of the most highly up-regulated genes (37) . In addition, mice that were deficient for the CCR5 ligand MIP-1␣/CCL3 exhibited milder arthritis (38) . We also recently showed that blocking of CCR5 in rat AIA resulted in reduced joint destruction (22) . Taken together, these findings indicate that CCR5 targeting is an interesting potential therapeutic approach, possibly in later rather than earlier stages of inflammatory arthritis.
SDF-1/CXCL12 has been demonstrated to be highly expressed in RA ST, and expression of its receptor, CXCR4, was observed on CD4ϩ T cells following their entry into the synovium (39, 40) . Surprisingly, we did not detect substantial CXCR4 expression on lymphocytes in ST from rats with AIA, suggesting that murine lymphocytes may play a different role than in human RA. Similarly, we demonstrated in an earlier study that CX 3 CR1 was virtually absent on lymphocytes during rat AIA (10), although it was clearly expressed on human T cells in the arthritic joint (13) . In contrast, CXCR4 was prominently expressed on ST ECs in rat AIA, starting on day 14 and preceding the inflammatory peak. Likewise, Burman and coworkers found high expression of the ligand SDF-1/CXCL12 on vascular endothelium in inflamed RA ST (41) . The expression of both receptor and ligand on ECs indicates a potential self-perpetuating pro-angiogenic mechanism, possibly via autocrine expression of vascular endothelial growth factor (42) . Also, these data support the notion of a potential role of CXCR4 in retention of inflammatory effector cells and transendothelial migration in the joint, thereby driving the inflammatory process (43) . EC expression of different chemokines may result in directional migration of leukocytes (26) , with CXCR4 being a crucial part of this intercellular communication.
Macrophages showed increased expression of CXCR4 starting on day 18 after AIA induction. Similarly, CXCR4 has been implicated in monocyte localization to inflamed RA ST (15) . In our study, ST lining cells expressed CXCR4 constitutively, followed by downregulation of CXCR4 in the early phase of AIA, suggesting a self-limiting process.
Interestingly, immunohistochemistry analysis revealed a cytoplasmic staining pattern for CXCR4, while immunofluorescence clearly identified the receptor on the cell surface. This is consistent with previous observations, reflecting the limitations of the detection method used (10, 11) . Additional in vitro experiments using the rat macrophage cell line NR8383 confirmed the predominant cell surface expression not only of CXCR4 but also of other receptors. Expression in response to LPS essentially paralleled the in vivo situation in early rat AIA. Thus, NR8383 cells may be a useful in vitro tool to study the inflammatory response in rat AIA, as previously shown for other inflammatory diseases (12, 44) .
Human interleukin-8 (IL-8)/CXCL8 is known to mediate inflammation in RA, and there is some evidence for a role for its receptor, CXCR1, in RA (45) . Although CXCR1 is present in rats, a rodent homolog of IL-8/CXCL8 has not been identified. In our study, CXCR1 was constitutively expressed on smooth muscle cells, with a subsequent decrease during AIA. As with CCR1 and CCR2, the role of the CXCR1 that is substantially constitutively expressed on synovial smooth muscle cells remains unclear. Conversely, lining cells and macrophages showed increased CXCR1 expression during the course of arthritis, indicating a possible role in maintaining the inflammatory process.
Results of staining for CXCR2 on both lining cells and macrophages suggested a potential role in the inflammatory phase, consistent with data regarding mediation of inflammation in RA by its ligands, likely via promotion of angiogenesis (46) . The chemokines IP-10/ CXCL10 and Mig/CXCL9 have been detected in human RA (47) , with their receptor CXCR3 demonstrated on ECs in inflamed tissue (48) . However, in the present study, staining for CXCR3 failed to reveal substantial expression on macrophages or ECs in rat ST, implying that this receptor may be part of leukocyte ingress in inflamed synovium only if expressed on the recruited cells.
A recent study demonstrated reduced severity of CIA in mice in response to inhibition of the CXCR5 ligand CXCL13 (49) , which indicated a potential role for CXCR5 in inflammatory arthritis. CXCR5 was also found to be up-regulated in human RA synovium (50) . Indeed, in our study, CXCR5 was also present on lining cells in normal and arthritic rat ST and showed minor expression on macrophages.
In summary, this study provides information on cell type-specific protein expression of CC and CXC chemokine receptors during the course of rat AIA. This knowledge of the temporospatial expression of chemokine receptors may help to optimize target-oriented blocking of chemokine receptors at different phases of inflammatory arthritis.
